Expand CLRB Menu
CLRB MENU

CLRB Stock Posts


CLRB #CellectarBiosciences stock declines -31.4% in premarket,

Premarket Decliner

CLRB Cellectar Biosciences2.77+0.11+4.1%

Premarket:1.90-0.87 (-31.4%)

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Globe NewswireWed, 23-Dec 8:38 AM
CLRB stock increases 54.6% in premarket,

Premarket Gainer

CLRB Cellectar Biosciences Inc.1.41+0.01+0.7%

Premarket:2.18+0.77 (+54.6%)

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia

Globe NewswireTue, 26-May 7:45 AM
CLRB stock declines -20.2% in premarket,

Premarket Decliner

CLRB Cellectar Biosciences Inc.2.82+0.54+23.7%

Premarket:2.25-0.57 (-20.2%)

Cellectar Biosciences Announces $10.0 Million Financing

Globe NewswireThu, 16-May 8:53 AM
CLRB stock increases 36.9% in premarket,

Premarket Gainer

CLRB Cellectar Biosciences Inc.2.74+0.40+17.1%

Premarket:3.75+1.01 (+36.9%)

FDA Grants Exemption to Import Alert for Cellectar's CLR 131 in Pediatric and Adolescent Patients

Globe NewswireTue, 19-Mar 8:30 AM
CLRB stock increases 33.7% in premarket,

Premarket Gainer

CLRB Cellectar Biosciences Inc.3.29+0.29+9.7%

Premarket:4.40+1.11 (+33.7%)

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

Globe NewswireTue, 2-Oct 8:00 AM
CLRB stock increases 8.4% in premarket,

Premarket Gainer

CLRB Cellectar Biosciences Inc.7.38-0.11-1.5%

Premarket:8.00+0.62 (+8.4%)

Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

Globe NewswireWed, 18-Jul 8:00 AM
Load Earlier Posts